Ballew Advisors’s iShares Biotechnology ETF IBB Stock Holding History

Ballew Advisors’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-107	Closed	-$11K	–	251
2018 Q3	$11K	Hold	107	–	–	0.01%	282
2018 Q2	$12K	Hold	107	–	–	0.01%	285
2018 Q1	$11K	Buy	+107	New	+$11.9K	0.01%	294

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Natixis Paris, France $28B AUM 26.79% 1-Year Est. Return

Ballew Advisors's IBB Position: Q4 2018 in Review

Ballew Advisors sold out of iShares Biotechnology ETF (IBB) in Q4 2018, closing a stake of 107 shares — an estimated $11K sold.

Ballew Advisors first reported a position in IBB in Q1 2018 and held it in 3 quarters. The position peaked at $12K in Q2 2018. 649 funds tracked by Wall St. Rank hold IBB as of Q4 2018.

Ballew Advisors reported no remaining iShares Biotechnology ETF position as of Q4 2018 after selling out during the quarter.
Ballew Advisors sold 107 iShares Biotechnology ETF shares in Q4 2018, an estimated $11K.
Ballew Advisors first reported a position in iShares Biotechnology ETF in Q1 2018 and held it in 3 quarters.
Ballew Advisors's iShares Biotechnology ETF position peaked at $12K in Q2 2018.
649 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q4 2018.

Based on Ballew Advisors's 13F filing for Q4 2018, filed 12 Feb 2019.